La investigación al frente del SARS-COV-2 y la COVID-19 en el departamento de enfermedades infecciosas del Hospital Universitario San Pedro-CIBIR
DOI:
https://doi.org/10.66737/ier.zub.276Keywords:
SARS-CoV-2, COVID-19, pandemic, research, infectious diseasesAbstract
During the pandemic caused by SARS-CoV-2, the causative agent of COVID-19, the Department of Infectious Diseases formed by its clinical team together with its more scientific side in the Center from Biomedical Research of La Rioja have worked hard to generate new knowledge to overcome this crisis from both a basic and clinic approach. This article summarizes the
different scientific articles published by the members of this multidisciplinary team.
Downloads
References
Berastegui-Cabrera, J., Salto-Alejandre, S., Valerio, M., Pérez-Palacios, P., Arnaiz-De Las Revillas, F., Abelenda-Alonso, G., ... & Sánchez-Céspedes, J. (2021). SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. Journal of Infection, 82(3), e38-e41. Berastegui-Cabrera, J. et al., (2021). SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load. J Infect, 82:e38-e41.1.
Blanco, J. R., Cobos-Ceballos, M. J., Navarro, F., Sanjoaquin, I., de Las Revillas, F. A., Bernal, E., ... & Ugedo, J. (2021). Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clinical Microbiology and Infection, 27(6), 892-896. Blanco, J.R. et al., (2021). Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect, 27:892-896. ConPlas-19 (2021). Disponible en: https://eu-isciii.es/covidfundinspain/multicenter-randomized-clinical-trial-of-convalescent-plasma-therapy-versusstandard-of-care-for-the-treatment-of-covid-19-in-hospitalized-patients/
Consorcio “Scourge” Determinantes genéticos y biomarcadores genómicos de riesgo en pacientes con infección por coronavirus Sars-CoV-2”. Disponible en: https://www.scourge-covid.org
COVID-19@Spain and COVID@HULP Study Groups (2021). Development and validation of a prediction model for 30-day mortality in hospitalized patients with COVID-19: the COVID-19 SEIMC score. Thorax, 76:920-929.
Cuervo, G., de Alarcón, A., Sousa, D., Barca, L. V., Fernández-Hidalgo, N., Gutiérrez-Carretero, E., ... & Acevedo, M. R. (2021). Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis. Clinical Microbiology and Infection, 27(4), 660-664. Escolà-Vergé, L. et al., (2021).. Cuervo G, de Alarcón A, Sousa D, Barca LV, Fernández-Hidalgo N, et al.,. Impact of the COVID-19 pandemic on the diagnosis, management and prognosis of infective endocarditis. Clin Microbiol Infect, 27:660-4.
Del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., ... & for The Spanish HIV/COVID-19 Collaboration*. (2020). Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Annals of internal medicine, 173(7), 536-541.The Spanish HIV/COVID-19 Collaboration (2020). Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study. Ann Intern Med, 173:536-41.
Gutiérrez-Gutiérrez, B., Del Toro, M. D., Borobia, A. M., Carcas, A., Jarrín, I., Yllescas, M., ... & Escudero, E. M. (2021). Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. The Lancet infectious diseases, 21(6), 783-792.REIPI-SEIMC COVID-19 group and COVID@HULP groups (2021). Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infect Dis, 21:783-792.
Íñiguez, M., Pérez-Matute, P., Villoslada-Blanco, P., Recio-Fernandez, E., Ezquerro-Perez, D., Alba, J., ... & Oteo, J. A. (2021). ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study. medRxiv. Íñiguez, M. et al., (2021). ACE gene variants rise the risk of severe COVID-19 in patients with hypertension, dyslipidemia or diabetes. A pilot study. Front Endocrinol (Lausanne). 12:688071. doi: 10.3389/fendo.2021.688071. eCollection 2021.
Ochoa-Callejero, L., García-Sanmartín, J., Villoslada-Blanco, P., Íñiguez, M., Pérez-Matute, P., Pujadas, E., ... & Martínez, A. (2021). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. Journal of the Endocrine Society, 5(3), bvaa199. Ochoa-Callejero, L. et al., (2021a). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 4, 5(3):bvaa199.
Ochoa-Callejero, L., García-Sanmartín, J., Villoslada-Blanco, P., Íñiguez, M., Pérez-Matute, P., Pujadas, E., ... & Martínez, A. (2021). Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. Journal of the Endocrine Society, 5(3), bvaa199.Ochoa-Callejero, L. et al., (2021b). Response to Letter to the Editor form Anis Abobaker. Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 17, 5(10):bvab053.
OSCAR (2021). Disponible en: https://clinicaltrials.gov/ct2/show/NCT04376684
Oteo, J. A., Marco, P., de León, L. P., Roncero, A., Lobera, T., & Lisa, V. (2020). A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications. medRxiv.Oteo, J.A. et al., (2020a). A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with moderate disease. A strategy associated with a reduction in hospital admissions and complications. Disponible en: https://www.medrxiv.orgcontent/10.1101/2020.06.10.20101105v1
Oteo, J.A. et al., (2020b). Characteristics and prevalence of pneumococal pneumonia infection in COVID-19 patients. ESCMID Conference on Coronavirus Disease (ECCVID). On line, 23-25 september 2020. Disponible en: https://www.eccvid.org/video-liste.php?p=29&&c=&t=&f=&a=&vt=& coday=&cotype=&coref=&coroom=&tri=&noCarousel=&nc=
Rodríguez-Baño, J., Pachón, J., Carratalà, J., Ryan, P., Jarrín, I., Yllescas, M.,... & Ruiz, J. P. (2021). Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection, 27(2), 244-252.SAM-COVID Study Group (2021). Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clin Microbiol Infect, 27:244-52.
Ruiz-Arrondo, I., Portillo, A., Palomar, A. M., Santibáñez, S., Santibáñez, P., Cervera, C., & Oteo, J. A. (2021). Detection of SARS-CoV-2 in pets living with COVID-19 owners diagnosed during the COVID-19 lockdown in Spain: A case of an asymptomatic cat with SARS-CoV-2 in Europe. Transboundary and emerging diseases, 68(2), 973-976. Ruiz-Arrondo, I. et al., (2020). Detection of SARS-CoV-2 in pets living with COVID-19 owners diagnosed during the COVID-19 lockdown in Spain: A case of an asymptomatic cat with SARS-CoV-2 in Europe. Transbound Emerg Dis, 68:973-6.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 José Oteo, Jorge Alba, José Blanco, Cristina Cervera, Lara García Álvarez, Concepción García-García, Valvanera Ibarra, María Iñiguez, Luis Metola, Sonia Omatos, Ana María Palomar, Galadriel Pellejero, Laura Pérez-Martínez, Patricia Pérez-Matute, Aranzazu Portillo, Emma Recio-Fernández, Lourdes Romero, Ignacio Ruiz-Arrondo, Paula Santibáñez, Sonia Santibáñez, Mercedes Sanz, Pablo Villoslada-Blanco (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en Zubía conservan los derechos de autor de sus trabajos y autorizan a la revista la primera publicación de los mismos.
Los artículos se publican bajo la licencia Creative Commons Atribución–No Comercial–Compartir Igual (CC BY-NC-SA), que permite su uso, distribución y reproducción en cualquier medio, siempre que se cite adecuadamente la autoría original, no se realice un uso comercial y se mantenga la misma licencia.
